Found 5 matching trials
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
PHASE2This is a multicenter, open-label study of Intratumoral Vusolimogene Oderpa...
Status
Active Not Recruiting
Location
University of California, San Francisco
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
EARLY_PHASE1This early-phase study will examine Vusolimogene Oderparepvec, a geneticall...
Location
UPMC Hillman Cancer Center
"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
PHASE1Neoadjuvant treatment is an important part of the treatment strategy for lo...
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
PHASE3This is a randomized, controlled, multicenter, open-label Phase 3 clinical ...
Location
Banner MD Anderson Cancer Center
An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma
N/AThe purpose of this EAP is to provide expanded access (i.e., before marketi...
Status
No Longer Available
Location
Multiple Locations